See more : Purple Biotech Ltd. (PPBT) Income Statement Analysis – Financial Results
Complete financial analysis of Axcella Health Inc. (AXLA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Axcella Health Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Cibus Nordic Real Estate AB (publ) (6N5.F) Income Statement Analysis – Financial Results
- NextNav Inc. (NN) Income Statement Analysis – Financial Results
- YU-WA Creation Holdings Co.,Ltd. (7615.T) Income Statement Analysis – Financial Results
- Taiwan Secom Co., Ltd. (9917.TW) Income Statement Analysis – Financial Results
- ING Groep N.V. (INN1.DE) Income Statement Analysis – Financial Results
Axcella Health Inc. (AXLA)
About Axcella Health Inc.
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 56.98M | 43.14M | 37.04M | 41.66M | 25.49M | 22.92M |
| General & Administrative | 15.82M | 18.71M | 16.80M | 15.78M | 8.41M | 6.01M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.82M | 18.71M | 16.80M | 15.78M | 8.41M | 6.01M |
| Other Expenses | 0.00 | -4.00K | 10.00K | 34.00K | 0.00 | 0.00 |
| Operating Expenses | 72.80M | 61.85M | 53.84M | 57.44M | 33.90M | 28.92M |
| Cost & Expenses | 72.80M | 61.85M | 53.84M | 57.44M | 33.90M | 28.92M |
| Interest Income | 504.00K | 139.00K | 306.00K | 1.81M | 0.00 | 0.00 |
| Interest Expense | 3.02M | 2.92M | 3.01M | 3.40M | 0.00 | 0.00 |
| Depreciation & Amortization | 412.00K | 288.00K | 419.00K | 51.00K | 1.07M | 1.39M |
| EBITDA | -67.01M | -61.85M | -53.84M | -57.39M | -32.81M | -27.61M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -72.80M | -61.85M | -53.84M | -57.44M | -33.90M | -28.92M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.39M | -2.78M | -2.69M | -1.60M | -2.17M | -2.02M |
| Income Before Tax | -81.19M | -64.63M | -56.53M | -59.04M | -36.07M | -30.94M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.49M | 2.28M | 936.00K | -2.17M | 2.02M |
| Net Income | -81.19M | -67.12M | -58.81M | -59.97M | -36.07M | -30.94M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.49 | -1.76 | -1.85 | -3.61 | -2.18 | -1.87 |
| EPS Diluted | -1.49 | -1.76 | -1.85 | -3.61 | -2.18 | -1.87 |
| Weighted Avg Shares Out | 54.36M | 38.11M | 31.75M | 16.62M | 16.53M | 16.53M |
| Weighted Avg Shares Out (Dil) | 54.36M | 38.11M | 31.75M | 16.62M | 16.53M | 16.53M |
Axcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA #EMMs--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will be participating in the Piper Sandler 33rd Annual...
5 Winning Stocks Backed by the Overlooked Rising P/E Ratio
Want to try an out-of-the-box approach? Tap five stocks, namely OMI, STKL, CASY, LAZY and AXLA, with increasing P/E ratios.
Is a Surprise Coming for Axcella Health (AXLA) This Earnings Season?
Axcella Health (AXLA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the third quarter ended September 30, 2021 and provided...
Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the third quarter ended September 30, 2021 and provided a...
Axcella Therapeutics Announces Upcoming Presentations at AASLD's The Liver Meeting® 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced two upcoming poster presentations at The Liver Meeting® 2021, the Annual Meeting...
Axcella Therapeutics Announces Upcoming Presentations at AASLD’s The Liver Meeting® 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced two upcoming poster presentations at The Liver Meeting® 2021, the Annual Meeting of...
Axcella To Test NASH Candidate In Long COVID Patients
Axcella Health Inc (NASDAQ: AXLA) has announced a new clinical program investigating AXA1125 as a potential treatment for patients with Long COVID. Symptoms last for months following recovery from the infection.
Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVID
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced a new clinical program to investigate AXA1125 as a potential treatment for patients...
Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVID
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA #LongCOVID--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced a new clinical program to investigate AXA1125 as a potential treatment...
Source: https://incomestatements.info
Category: Stock Reports